XML 101 R81.htm IDEA: XBRL DOCUMENT v3.20.4
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
Jun. 01, 2020
Nov. 30, 2020
Feb. 28, 2019
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2020
Noncontrolling Interest [Line Items]                        
Payments to acquire additional interest in subsidiaries                 $ 1,399,999 $ 0 $ 0  
Gain on deconsolidation of Geneos       $ 0 $ 0 $ 4,121,075 $ 0   4,121,075 0 0  
Share in net loss of Geneos       1,923,179 $ 1,759,674 $ 901,757 $ 0   4,584,610 0 $ 0  
Investment in Geneos       $ 434,387       $ 434,387 $ 434,387 $ 0    
Series A-1 Preferred Stock                        
Noncontrolling Interest [Line Items]                        
Investment in Geneos $ 1,399,999                      
Geneos Therapeutics, Inc.                        
Noncontrolling Interest [Line Items]                        
Noncontrolling interest, ownership percentage by parent   36.00% 61.00%     47.00% 52.00%          
Percentage of ownership       47.00%       47.00% 47.00%      
Geneos Therapeutics, Inc.                        
Noncontrolling Interest [Line Items]                        
Payments to acquire additional interest in subsidiaries   $ 1,400,000 $ 1,200,000                  
Stock purchase agreement, commitment of additional investment           $ 800,000           $ 800,000
Gain on deconsolidation of Geneos 4,121,075                      
Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value 2,400,000                      
Share in net loss of Geneos               $ 4,584,610        
Investment in Geneos 3,618,998     $ 434,387       434,387 $ 434,387      
Geneos Therapeutics, Inc. | Common stock                        
Noncontrolling Interest [Line Items]                        
Share in net loss of Geneos               819,000        
Investment in Geneos $ 819,000     0       0 0      
Geneos Therapeutics, Inc. | Series A-1 Preferred Stock                        
Noncontrolling Interest [Line Items]                        
Share in net loss of Geneos               3,800,000        
Investment in Geneos       $ 434,000       $ 434,000 $ 434,000